Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taselisib plus fulvestrant versus placebo plus fulvestrant in ER-positive/HER2-negative advanced or metastatic breast cancer after aromatase inhibitor therapy
2014-003185-25Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Taselisib plus fulvestrant with Placebo plus fulvestrant (2 arms). Primary endpoint: Progression-free survival. Started Jan 2015; status: completed.
02
Drugs
taselisib / pictilisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-003185-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003185-25.